Calculus EIS Fund was the first approved EIS Fund on the market 22nd iteration of the Fund launched this week The last 18 months have seen 10 exits across the EIS Funds including 6x return for ActiveOps Calculus Capital are delighted to launch the Calculus EIS Fund offering an opportunity to invest in entrepreneurial businesses … Continued
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces U.S. Food and Drug Administration (FDA) clearance of the Group’s Investigational New Drug (IND) application for AT247, the Group’s proprietary wholly owned ultra-rapid insulin for the treatment of diabetes. The IND supports a Phase I clinical trial in … Continued
Hardman & Co’s latest EIS Navigator Podcast Episode, hosted by Dr Brian Moretta FFA, featured Calculus Capital CEO John Glencross on the topic of “long term perspective on EIS and VCT investing”. You can listen below.
Approval granted for clinical trial in South Africa Vaccine targets the core of the virus, not just the spike protein eliciting a t-cell response which can destroy cells infected with any SARS CoV-2 variants and other SARS-CoV viruses that may emerge in the future. Scancell, the developer of novel immunotherapies for the treatment of cancer … Continued
Brouhaha Entertainment was founded by experienced producers: Oscar nominated Gabrielle Tana, Independent film industry pioneer Troy Lum and producer Andrew Mason Founders have successfully produced 27 films and 9 television projects to date, featuring top talent from around the globe Investment will be used to expand the team and fund development in film and particularly … Continued
Calculus successfully exit Mologic by sale to new philanthropic entity Global Access Health London 19 July 2021: Calculus Capital (“Calculus”), pioneers of the tax efficient investment industry, is pleased to announce the successful sale of Mologic Limited (“Mologic” or “the Company”), a world leading innovator in lateral flow and rapid diagnostic technologies, and founder of … Continued
The Annual General Meeting (AGM) of Calculus VCT plc (the “Company”) will be held at 12.30pm on 8 July 2021. The AGM is an important event in the Company’s corporate calendar, providing an opportunity for shareholders to meet the board and put questions to the directors and the investment manager, as well as enabling shareholders … Continued
Calculus VCT has invested £0.5m into Spectral MD through an oversubscribed inital public offering onto AIM, on Tuesday 22 June. The Dallas-based firm, which is building notable presence in the UK as part of its product launch effort, produces predictive analytics, proprietary AI algorithms and imaging systems to assist with medical treatment. Spectral MD’s technology, … Continued
22 June 2021 – Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces an update on COVIDITY clinical trial plans and the publication of preclinical data on two vaccine candidates from its COVIDITY research programme. The COVIDITY programme is a collaboration between Scancell and … Continued
Arecor announced its admission to trading on AIM, a market operated by London Stock Exchange, on 3 June 2021. Admission follows a successful oversubscribed placing by Panmure Gordon, raising gross proceeds of £20 million at a price of 226 pence per share. On Admission the Company will have a market capitalisation of approximately £62.5 million. … Continued